Chemotherapy protocols and incidence of oral mucositis. An integrative review
M Curra, LAV Soares, MD Martins, PSS Santos - Einstein (Sao Paulo), 2018 - SciELO Brasil
This review aimed to analyze the scientific production on severity of oral mucositis as an
adverse effect of chemotherapy. To this end, we performed a search at PubMed databases …
adverse effect of chemotherapy. To this end, we performed a search at PubMed databases …
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
L Lee, T Ito, RT Jensen - Expert opinion on pharmacotherapy, 2018 - Taylor & Francis
Introduction: Since the initial approval of everolimus in 2011, there have been a number of
important changes in therapeutic/diagnostic modalities as well as classification/staging …
important changes in therapeutic/diagnostic modalities as well as classification/staging …
[HTML][HTML] Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society
of Clinical Oncology Guideline - University of Miami Logo image Menu Find research works …
of Clinical Oncology Guideline - University of Miami Logo image Menu Find research works …
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3 …
Background mTOR inhibition reverses trastuzumab resistance via the hyperactivated
PIK/AKT/mTOR pathway due to PTEN loss, by sensitising PTEN-deficient tumours to …
PIK/AKT/mTOR pathway due to PTEN loss, by sensitising PTEN-deficient tumours to …
Renal effects of targeted anticancer therapies
C Porta, L Cosmai, M Gallieni, P Pedrazzoli… - Nature Reviews …, 2015 - nature.com
The use of novel targeted anticancer agents has led to overall improvement in the prognosis
of many patients affected by various malignancies, but has also been associated with an …
of many patients affected by various malignancies, but has also been associated with an …
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer
Abstract The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …
rapamycin) signalling pathway is an established driver of oncogenic activity in human …
Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology
Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and
debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ …
debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ …
[HTML][HTML] Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer
J O'Shaughnessy, JT Beck, M Royce - Cancer treatment reviews, 2018 - Elsevier
Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and
mortality among women worldwide. Endocrine therapy is the standard of care for the most …
mortality among women worldwide. Endocrine therapy is the standard of care for the most …
Therapeutic potential of quercetin on human breast cancer in different dimensions
N Kasiri, M Rahmati, L Ahmadi, N Eskandari… - …, 2020 - Springer
Background There has been an extensive range of incidence and mortality of breast cancer
(BC), and the comprehensively available treatments for BC have not been completely …
(BC), and the comprehensively available treatments for BC have not been completely …
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study
Lymphangioleiomyomatosis is a rare, progressive cystic lung disorder characterised by
dysregulated activation of mammalian target of rapamycin (mTOR) signalling. This was a …
dysregulated activation of mammalian target of rapamycin (mTOR) signalling. This was a …